Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy, Conformal | 9 | 2004 | 51 | 0.400 |
Why?
|
| Radiosurgery | 3 | 2015 | 135 | 0.310 |
Why?
|
| Prostatic Neoplasms | 7 | 2004 | 1419 | 0.190 |
Why?
|
| Trigeminal Neuralgia | 1 | 2002 | 6 | 0.180 |
Why?
|
| Multiple Sclerosis | 1 | 2002 | 390 | 0.140 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 11 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 1281 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2003 | 100 | 0.100 |
Why?
|
| Brain Neoplasms | 4 | 2004 | 1300 | 0.100 |
Why?
|
| Xerostomia | 2 | 2003 | 13 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 3 | 2003 | 634 | 0.090 |
Why?
|
| Radiation Injuries | 2 | 2003 | 147 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 327 | 0.090 |
Why?
|
| Genetic Therapy | 2 | 2004 | 726 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2015 | 377 | 0.070 |
Why?
|
| Follow-Up Studies | 6 | 2015 | 5298 | 0.060 |
Why?
|
| Parotid Gland | 2 | 2003 | 18 | 0.060 |
Why?
|
| Radiometry | 2 | 2003 | 48 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 1001 | 0.060 |
Why?
|
| Radiotherapy Dosage | 5 | 2004 | 216 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2005 | 100 | 0.050 |
Why?
|
| Prostatectomy | 2 | 2003 | 313 | 0.050 |
Why?
|
| Acyclovir | 1 | 2004 | 47 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2004 | 89 | 0.050 |
Why?
|
| Valine | 1 | 2004 | 110 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 164 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 236 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2005 | 1261 | 0.050 |
Why?
|
| Neuroma, Acoustic | 1 | 2002 | 29 | 0.050 |
Why?
|
| Middle Aged | 12 | 2015 | 28911 | 0.050 |
Why?
|
| Immobilization | 1 | 2002 | 23 | 0.050 |
Why?
|
| Hearing | 1 | 2002 | 61 | 0.040 |
Why?
|
| Aged | 12 | 2015 | 21279 | 0.040 |
Why?
|
| Radiation Oncology | 1 | 2002 | 28 | 0.040 |
Why?
|
| Simplexvirus | 1 | 2002 | 100 | 0.040 |
Why?
|
| Rectum | 1 | 2002 | 103 | 0.040 |
Why?
|
| Meningioma | 1 | 2002 | 137 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 1357 | 0.040 |
Why?
|
| Catheterization | 1 | 2002 | 234 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2004 | 347 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2015 | 6922 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 732 | 0.040 |
Why?
|
| Adult | 9 | 2015 | 31734 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2002 | 321 | 0.040 |
Why?
|
| Male | 14 | 2015 | 65357 | 0.030 |
Why?
|
| Medulloblastoma | 1 | 2002 | 385 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1325 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 54 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2003 | 2123 | 0.030 |
Why?
|
| Humans | 16 | 2015 | 131967 | 0.030 |
Why?
|
| Female | 9 | 2015 | 71316 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2003 | 62 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2015 | 13011 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2004 | 586 | 0.020 |
Why?
|
| Biopsy | 2 | 2004 | 1252 | 0.020 |
Why?
|
| Time Factors | 3 | 2002 | 6285 | 0.020 |
Why?
|
| Antiviral Agents | 2 | 2004 | 813 | 0.020 |
Why?
|
| Prednisone | 1 | 2005 | 246 | 0.010 |
Why?
|
| Vincristine | 1 | 2005 | 194 | 0.010 |
Why?
|
| Flutamide | 1 | 2004 | 26 | 0.010 |
Why?
|
| Leuprolide | 1 | 2004 | 23 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2003 | 17703 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 301 | 0.010 |
Why?
|
| Prodrugs | 1 | 2004 | 56 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2004 | 114 | 0.010 |
Why?
|
| Dysgeusia | 1 | 2003 | 1 | 0.010 |
Why?
|
| Salivation | 1 | 2003 | 6 | 0.010 |
Why?
|
| Thirst | 1 | 2003 | 5 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 762 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 441 | 0.010 |
Why?
|
| Groin | 1 | 2003 | 14 | 0.010 |
Why?
|
| Speech Disorders | 1 | 2003 | 48 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2003 | 28 | 0.010 |
Why?
|
| Facial Nerve | 1 | 2002 | 25 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 175 | 0.010 |
Why?
|
| Cranial Nerves | 1 | 2002 | 21 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 4058 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 256 | 0.010 |
Why?
|
| Penile Erection | 1 | 2002 | 80 | 0.010 |
Why?
|
| Audiometry | 1 | 2002 | 22 | 0.010 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2002 | 3 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2002 | 102 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2002 | 60 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 433 | 0.010 |
Why?
|
| Prostate | 1 | 2004 | 415 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2003 | 141 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 646 | 0.010 |
Why?
|
| Morbidity | 1 | 2002 | 261 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 907 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1522 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2003 | 204 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 910 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 989 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 838 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 1457 | 0.010 |
Why?
|
| Adolescent | 3 | 2002 | 21008 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 710 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 496 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 505 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2002 | 15066 | 0.010 |
Why?
|
| Quality of Life | 1 | 2002 | 2116 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4762 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1545 | 0.010 |
Why?
|
| Child | 2 | 2002 | 26332 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 13332 | 0.000 |
Why?
|
| Mice | 1 | 2002 | 18504 | 0.000 |
Why?
|
| Animals | 1 | 2002 | 34460 | 0.000 |
Why?
|